161 related articles for article (PubMed ID: 17414056)
1. Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer.
Fujino Y; Ueda T; Kamigaki T; Takase S; Ajiki T; Kamoda Y; Matsumoto I; Yasuda T; Kuroda Y
Pancreas; 2007 Apr; 34(3):335-9. PubMed ID: 17414056
[TBL] [Abstract][Full Text] [Related]
2. Postoperative gemcitabine alone and concurrent with radiation therapy in locally advanced pancreatic carcinoma.
Ozkok S; Demirci S; Yalman D; Zeytunlu M; Nart D; Yuzer Y; Coker A; Goker E
Tumori; 2010; 96(4):560-7. PubMed ID: 20968135
[TBL] [Abstract][Full Text] [Related]
3. [Gemcitabine treatment in patients with stage IV pancreatic cancer and prognostic factors for survival of patients with stage IVb(a retrospective survey at 15 hospitals in Niigata Prefecture)].
Ohta H; Shioji K; Maruyama Y; Watanabe K; Aiba T; Baba Y; Seki K; Yanagi M; Iiri T; Ishizuka K; Isokawa O; Nakamura A; Natsui M; Furukawa K; Suzuki Y; Ban-Nai H; Motoyama N; Mori S; Aoyagi Y
Gan To Kagaku Ryoho; 2008 Dec; 35(13):2357-61. PubMed ID: 19098402
[TBL] [Abstract][Full Text] [Related]
4. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer.
Ren J; Wu S; Su T; Ding J; Chen F; Li J; Wang Z; Han L; Wu Z
Cancer Med; 2024 May; 13(9):e7229. PubMed ID: 38698688
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
An SG; Kim DU; Song GA; Jang AL
Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
[TBL] [Abstract][Full Text] [Related]
6. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
[TBL] [Abstract][Full Text] [Related]
7. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemcitabine or S-1.
Aoyama T; Murakawa M; Katayama Y; Shiozawa M; Ueno M; Morimoto M; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(138):472-7. PubMed ID: 25916085
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
[TBL] [Abstract][Full Text] [Related]
9. Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.
Kurihara T; Kogo M; Ishii M; Yoneyama K; Kitamura K; Shimada K; Shimizu S; Yoshida H; Kiuchi Y
Hepatogastroenterology; 2015; 62(138):478-84. PubMed ID: 25916086
[TBL] [Abstract][Full Text] [Related]
10. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
[TBL] [Abstract][Full Text] [Related]
11. Palliative pancreatectomy with postoperative gemcitabine for patients with advanced pancreatic cancer.
Fujino Y; Sakai T; Kuroda Y
J Gastroenterol; 2008; 43(3):233-8. PubMed ID: 18373166
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience.
Kurosaki I; Hatakeyama K
Chemotherapy; 2005 Oct; 51(6):305-10. PubMed ID: 16224180
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Oettle H; Neuhaus P; Hochhaus A; Hartmann JT; Gellert K; Ridwelski K; Niedergethmann M; Zülke C; Fahlke J; Arning MB; Sinn M; Hinke A; Riess H
JAMA; 2013 Oct; 310(14):1473-81. PubMed ID: 24104372
[TBL] [Abstract][Full Text] [Related]
14. [Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective].
Wilkowski R; Thoma M; Heinemann V; Rau HG; Wagner A; Stoffregen C; Dühmke E
Strahlenther Onkol; 2003 Feb; 179(2):78-86. PubMed ID: 12590317
[TBL] [Abstract][Full Text] [Related]
15. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.
Sawaki A; Kanemitsu Y; Mizuno N; Takahashi K; Nakamura T; Ioka T; Tanaka S; Nakaizumi A; Salem AA; Ueda R; Yamao K
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1292-7. PubMed ID: 18700899
[TBL] [Abstract][Full Text] [Related]
16. Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data.
Wendling T; Mistry H; Ogungbenro K; Aarons L
Cancer Chemother Pharmacol; 2016 May; 77(5):927-38. PubMed ID: 26940939
[TBL] [Abstract][Full Text] [Related]
17. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
[TBL] [Abstract][Full Text] [Related]
18. Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
Hashimoto K; Ueno H; Ikeda M; Kojima Y; Hagihara A; Kondo S; Morizane C; Okusaka T
Oncology; 2009; 77(3-4):217-23. PubMed ID: 19729980
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A; Kos FT; Algin E; Yildiz R; Berk V; Tugba Unek I; Colak D; Colak D; Kucukoner M; Tamer Elkiran E; Helvaci K; Geredeli C; Dane F; Balakan O; Ali Kaplan M; Gok Durnali A; Harputoglu H; Goksel G; Ozdemir N; Buyukberber S; Gumus M; Ozkan M; Benekli M; Isikdogan A;
J BUON; 2012; 17(1):102-5. PubMed ID: 22517701
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Brasiūnas V; Brasiūniene B; Juozaityte E; Barauskas G
Medicina (Kaunas); 2004; 40(11):1074-80. PubMed ID: 15547308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
